



STATE OF WEST VIRGINIA
OFFICE OF THE ATTORNEY GENERAL
DARRELL V. MCGRAW, JR.
CONSUMER PROTECTION DIVISION
1-800-368-8808 or 304-558-8986

Press Release

January 20, 2004

FOR IMMEDIATE RELEASE CONTACT: DOUGLAS L. DAVIS
304-558-8986
1-800-368-8808

DEADLINE TO FILE CLAIMS IN THE TAXOL® SETTLEMENT RE-EXTENDED THROUGH FEBRUARY 29, 2004

Attorney General Darrell McGraw announced today that the deadline to file claims in the Taxol® antitrust case has been extended through February 29, 2004. Cancer patients who took the prescription drug Taxol® or its generic equivalent, paclitaxel, between January 1, 1999 and February 28, 2003, or their heirs, may be entitled to money from a \$12.5 million fund created as part of a settlement of an antitrust lawsuit brought by Attorney General McGraw and the attorneys general of the other states and territories. The case alleged that consumers purchasing Taxol®/paclitaxel were unlawfully overcharged.

The settlement received final approval on November 19, 2003, from the U.S. District Court for the District of Columbia. The settlement provides \$55 million in cash, with \$12.5 million set aside for consumers in restitution for overcharges they paid. Additionally, approximately \$7.5 million worth of Taxol® will be provided to the states for compassionate care treatment of lower income cancer patients. Claim forms and complete information can be obtained from the Claims Administrator at www.taxolsettlement.com, by calling 1-800-659-7609, or by calling Attorney General McGraw's consumer hotline, 1-800-368-8808. Claims must be postmarked no later than February 29, 2004.

"With the extension of the deadline to February 29, we hope that more people will be able to take advantage of this settlement," said Attorney General McGraw. Individuals could receive funds in the range of \$400 - \$2,600 and some could be eligible for inclusion in the compassionate care treatment group.

Taxol® is Bristol-Myers Squibb's brand name for the cancer drug paclitaxel (also marketed as Onxol®), an FDA-approved treatment for non-small cell lung cancer, breast and ovarian cancers and AIDS-related Kaposi's sarcoma.

###